

severe tumor lysis syndrome (TLS), and central nervous system (CNS) toxicities. Furthermore, since the introduction of monoclonal anti-CD20 antibodies such as rituximab, it has become more challenging to find effective therapies for the large proportion of patients who have prior exposure to anti-CD20 antibodies in their treatments.

5 Elderly patients (e.g., patients aged about 65 years or older) with FL experience more treatment-related difficulties than younger patients due to increased comorbidities, reduced immune function, and access to fewer treatment options (Castellino A, et al. *Mediterr J Hematol Infect Dis* 2017; 9:e2017009; Casulo C, et al. *Blood Adv* 2021; 5:1737–1745). Thus, there is an unmet need in the field for the development of efficacious methods of treating B cell proliferative disorders (e.g., non-
10 Hodgkin's lymphoma (NHL); e.g., follicular lymphoma (FL), transformed FL (trFL), or diffuse large B cell disorder (DLBCL), particularly relapsed and/or refractory (R/R) NHL, FL, trFL, or DLBCL) that achieve a more favorable benefit-risk profile in elderly patients (e.g., patients aged about 65 years or older).

15 SUMMARY

The present disclosure relates to methods of treating a subject (e.g., an elderly subject, e.g., a subject aged about 65 years or older) having a relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL) (e.g., an R/R follicular lymphoma (FL), R/R transformed FL (trFL), or R/R diffuse large B cell lymphoma (DLBCL)) by administration (e.g., intravenous administration) of an anti-
20 CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).

The disclosure is based, in part, on the discovery that dosing regimens involving administration of a bispecific antibody that binds to CD20 and CD3 (e.g., mosunetuzumab) over multiple dosing cycles (e.g., wherein the first dosing cycle is a step-up, fractionated dosing cycle) including a relatively high third dose (C1D3) and/or a dose of a second dosing cycle (C2D1) ("loading
25 doses") that is greater in amount than a dose of the third dosing cycle (C3D1) and/or additional dosing cycles ("base doses") can effectively treat elderly subjects (e.g., subjects aged about 65 years or older) having a B cell disorder while reducing toxicity (e.g., cytokine release syndrome and/or severe adverse events). The dosing regimens of the present disclosure have also been discovered to be particularly efficacious in the treatment of elderly subjects (e.g., subjects aged about 65 years or
30 older).

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a subject aged about 65 years or older having a relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), wherein mosunetuzumab is formulated for intravenous
35 administration to the subject according to a dosing regimen comprising at least a first dosing cycle, a second dosing cycle, and a third dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is about 60 mg; and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab, wherein the C3D1 is about
40 30 mg. In one example, the disclosure provides a method of treating a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having a relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL; e.g., R/R follicular lymphoma (FL), R/R transformed FL (trFL), or R/R diffuse large B cell lymphoma (DLBCL)) comprising intravenously administering to the subject
45 mosunetuzumab in a dosing regimen comprising at least a first dosing cycle, a second dosing cycle, and a third dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab, wherein the C1D1 is about 1 mg (e.g., 1 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, or $\pm$ 0.1 mg; e.g., 1 mg), the C1D2 is about 2 mg (e.g., 2 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, or $\pm$ 0.2 mg; e.g., 2 mg),
50 and the C1D3 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$

0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab, wherein the C3D1 is about 30 mg (e.g., 30 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, or $\pm$ 3 mg; e.g., 30 mg). In some examples, the C1D1 is 1 $\pm$ 0.2 mg, the C1D2 is 2 $\pm$ 0.4 mg, the C1D3 is 60 $\pm$ 12 mg, the C2D1 is 60 $\pm$ 12 mg, and the C3D1 is 30 $\pm$ 6 mg.

In some examples, the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy. In some examples, the two or more prior lines of therapy comprise an anti-CD20 monoclonal antibody (e.g., rituximab), an alkylating agent (e.g., bendamustine, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, carmustine, lomustine, streptozocin, busulfan, dacarbazine, temozolomide, altretamine, or thiotepa), or both an anti-CD20 monoclonal antibody and an alkylating agent.

In some examples, the R/R NHL is R/R follicular lymphoma (FL), R/R transformed FL (trFL), or R/R diffuse large B cell lymphoma (DLBCL). In a particular example, the R/R NHL is R/R FL. In some examples, the R/R FL is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. *Blood* 2016; 127:2375-90).

In some examples, the first, second, and third dosing cycles are 21-day ($\pm$ 1 day) dosing cycles. In some examples, the method comprises administering the C1D1, the C1D2, and the C1D3 on Days 1, 8 ($\pm$ 1 day), and 15 ($\pm$ 1 day), respectively, of the first dosing cycle. In some examples, the method comprises administering the C2D1 on Day 1 of the second dosing cycle. In some examples, the method comprises administering the C3D1 on Day 1 of the third dosing cycle.

In some examples, the dosing regimen further comprises one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, or more) additional dosing cycles. In some examples, the dosing regimen comprises five to 14 (five, six, seven, eight, nine, ten, 11, 12, 13, or 14) additional dosing cycles. In a particular example, the dosing regimen comprises five additional dosing cycles. In another particular example, the dosing regimen comprises 14 additional dosing cycles. In some examples, the one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, or more) additional dosing cycles are each 21-day ($\pm$ 1 day) dosing cycles.

In some examples, each of the one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, or more) of the additional dosing cycles comprises an additional single dose of mosunetuzumab. In some examples, the additional single dose of mosunetuzumab is administered to the subject on Day 1 of each respective additional dosing cycle. In some examples, the additional single dose of mosunetuzumab is about 30 mg (e.g., 30 mg $\pm$ 0.01 mg, $\pm$

0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, or $\pm$ 3 mg; e.g., 30 mg). In some examples, each additional dose of mosunetuzumab is 30 ± 6 mg.

In some examples, mosunetuzumab is administered by intravenous infusion.

5 In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a population of subjects aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to each subject in the population according to a dosing regimen comprising at least a first 21-day dosing cycle, a second 21-day dosing cycle, and a third 21-day dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab to be administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg. In one example, the disclosure provides a method of treating a population of subjects aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to each subject mosunetuzumab in a dosing regimen comprising at least a first 21-day ($\pm$ 1 day) dosing cycle, a second 21-day ($\pm$ 1 day) dosing cycle, and a third 21-day ($\pm$ 1 day) dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 ($\pm$ 1 day), and 15 ($\pm$ 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., $1 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, or $\pm 0.1 \text{ mg}$; e.g., 1 mg), the C1D2 about 2 mg (e.g., $2 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, or $\pm 0.2 \text{ mg}$; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., $60 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 6 \text{ mg}$; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., $60 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 6 \text{ mg}$; e.g., 60 mg); and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg (e.g., $30 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, or $\pm 3 \text{ mg}$; e.g., 30 mg). In some examples, the C1D1 is $1 \pm 0.2 \text{ mg}$, the C1D2 is $2 \pm 0.4 \text{ mg}$, the C1D3 is $60 \pm 12 \text{ mg}$, the C2D1 is $60 \pm 12 \text{ mg}$, and the C3D1 is $30 \pm 6 \text{ mg}$.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a population of subjects aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to each subject in the population according to a dosing regimen comprising eight 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg. In one example, the disclosure provides a method of treating a population of subjects aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to each subject mosunetuzumab in a dosing regimen comprising eight 21-day ($\pm$ 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 ($\pm$ 1 day), and 15 ($\pm$ 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., $1 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, or $\pm 0.1 \text{ mg}$; e.g., 1 mg), the C1D2 about 2 mg (e.g., $2 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, or $\pm 0.2 \text{ mg}$; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., $60 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 6 \text{ mg}$; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., $60 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 6 \text{ mg}$; e.g., 60 mg); and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg (e.g., $30 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 6 \text{ mg}$; e.g., 30 mg).

mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg (e.g., $30 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, or $\pm 3 \text{ mg}$; e.g., 30 mg). In some examples, the C1D1 is $1 \pm 0.2 \text{ mg}$, the C1D2 is $2 \pm 0.4 \text{ mg}$, the C1D3 is $60 \pm 12 \text{ mg}$, the C2D1 is $60 \pm 12 \text{ mg}$, and each of the C3D1-C8D1 is $30 \pm 6 \text{ mg}$.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a population of subjects aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to each subject in the population according to a dosing regimen comprising 17 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg. In one example, the disclosure provides a method of treating a population of subjects aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to each subject mosunetuzumab in a dosing regimen comprising 17 21-day (± 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., $1 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, or $\pm 0.1 \text{ mg}$; e.g., 1 mg), the C1D2 about 2 mg (e.g., $2 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, or $\pm 0.2 \text{ mg}$; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., $60 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 6 \text{ mg}$; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., $60 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 6 \text{ mg}$; e.g., 60 mg); and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg (e.g., $30 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, or $\pm 3 \text{ mg}$; e.g., 30 mg). In some examples, the C1D1 is $1 \pm 0.2 \text{ mg}$, the C1D2 is $2 \pm 0.4 \text{ mg}$, the C1D3 is $60 \pm 12 \text{ mg}$, the C2D1 is $60 \pm 12 \text{ mg}$, and each of the C3D1-C17D1 is $30 \pm 6 \text{ mg}$.

In some examples, the objective response rate in the population of subjects is $\geq 65\%$ (e.g., $\geq 70\%$, $\geq 75\%$, $\geq 80\%$, $\geq 85\%$, $\geq 90\%$, or $\geq 95\%$; e.g., 65-100%, 70-100%, 75-100%, 80-100%, 85-100%, 90-100%, 95-100%, 65-90%, 65-80%, 65-70%, 75-90%, 75-85%, 70-90%, or 80-90%; e.g., about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some examples, the objective response rate in the population of subjects is $\geq 75\%$. In some examples, the objective response rate in the population of subjects is $\geq 85\%$. In some examples, the objective response rate in the population of subjects is $\geq 90\%$.

In some examples, the complete response rate in the population of subjects is $\geq 50\%$ (e.g., $\geq 55\%$, $\geq 60\%$, $\geq 65\%$, $\geq 70\%$, $\geq 75\%$, $\geq 80\%$, $\geq 85\%$, $\geq 90\%$, or $\geq 95\%$; e.g., 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 50-90%, 50-80%, 50-70%, 50-60%, 50%-75%, 75-90%, 60-80%, 75-85%, 70-90%, or 80-90%; e.g., about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some

examples, the complete response rate in the population of subjects is $\geq 60\%$. In some examples, the complete response rate in the population of subjects is $\geq 70\%$.

In some examples, $\geq 40\%$ (e.g., $\geq 45\%$, $\geq 50\%$, $\geq 55\%$, $\geq 60\%$, $\geq 65\%$, $\geq 70\%$, $\geq 75\%$, $\geq 80\%$, $\geq 85\%$, $\geq 90\%$, or $\geq 95\%$; e.g., 40-100%, 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 40-90%, 40-80%, 40-70%, 40-60%, 40-50%, 50%-70%, 50-60%, 75-90%, 60-80%, 75-85%, 70-90%, or 80-90%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%) of subjects having an objective response maintained remission for 18 months. In some examples, $\geq 50\%$ of subjects having an objective response maintained remission for 18 months.

In some examples, $\geq 50\%$ (e.g., $\geq 55\%$, $\geq 60\%$, $\geq 65\%$, $\geq 70\%$, $\geq 75\%$, $\geq 80\%$, $\geq 85\%$, $\geq 90\%$, or $\geq 95\%$; e.g., 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 50-90%, 50-80%, 50-70%, 50-60%, 50%-75%, 75-90%, 60-80%, 75-85%, 70-90%, or 80-90%; e.g., about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%) of subjects having a complete response maintained complete remission for 18 months. In some examples, $\geq 60\%$ of subjects having a complete response maintained complete remission for 18 months.

In some examples, the median duration of response in the population of subjects is ≥ 9 months (e.g., ≥ 9 , 10, 11, 12, 13, 14, 15, 18, 21, 24, 27, 30, 33, 36 months, or more; e.g., 9-12 months, 9-15 months, 9-18 months, 9-24 months, 12-18 months, 12-24 months, 12-36 months, 18-36 months, 24-36 months, or more; e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 27, 30, 33, 36 months, or more). In some examples, the median duration of response in the population of subjects is ≥ 15 months. In some examples, the median duration of response in the population of subjects is ≥ 18 months.

In some examples, the median duration of complete response in the population of subjects is ≥ 12 months (e.g., ≥ 12 , 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 27, 30, 33, 36 months, or more; e.g., 12-15 months, 12-18 months, 12-21 months, 12-24 months, 12-30 months, 12-36 months, 15-18 months, 15-24 months, 18-24 months, 24-36 months, 18-36 months, or more; e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 27, 30, 33, 36 months, or more). In some examples, the median duration of complete response in the population of subjects is ≥ 16 months. In some examples, the median duration of complete response in the population of subjects is ≥ 18 months.

In some examples, $\geq 35\%$ of subjects (e.g., $\geq 40\%$, $\geq 45\%$, $\geq 50\%$, $\geq 55\%$, $\geq 60\%$, $\geq 65\%$, $\geq 70\%$, $\geq 75\%$, $\geq 80\%$, $\geq 85\%$, $\geq 90\%$, or $\geq 95\%$; e.g., 35-100%, 40-100%, 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 35-90%, 35-80%, 35-70%, 35-60%, 35-50%, 35-45%, 40-80%, 40-60%, 50%-70%, 50-60%, 75-90%, 60-80%, 75-85%, 70-90%, or 80-90%; e.g., about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%) have a progression-free survival of 18 months. In some examples, $\geq 45\%$ of subjects have a progression-free survival of 18 months.

In some examples, the median progression-free survival in the population of subjects is ≥ 12 months (e.g., ≥ 12 , 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 27, 30, 33, 36 months, or more; e.g., 12-15 months, 12-18 months, 12-21 months, 12-24 months, 12-30 months, 12-36 months, 15-18 months,

15-24 months, 18-24 months, 24-36 months, 18-36 months, or more; e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 27, 30, 33, 36 months, or more). In some examples, the median progression-free survival in the population of subjects is ≥ 17 months.

5 In some examples, the rate of serious adverse events, excluding Grade 5 malignant neoplasm progression, in the population of subjects is $\leq 45\%$ (e.g., $\leq 40\%$, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; e.g., 0-45%, 0-35%, 0-25%, 0-15%, 0-10%, 0-5%, 5-15%, 15-30%, 30-45%, 10-30%, 20-40%, 35-45%, 30-40%, 20-30%, or 10-20%; e.g., about 0%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40% or about 45%). In some examples, the rate of serious adverse events, excluding Grade 5 malignant neoplasm progression, in the population of subjects is $\leq 40\%$. In some examples, the rate of serious adverse events, excluding Grade 5 malignant neoplasm progression, in the population of subjects is $\leq 50\%$ (e.g., about 50%, about 49%, about 48%, about 47%, or about 46%).

10 In some examples, the rate of serious adverse events related to mosunetuzumab in the population of subjects is $\leq 40\%$ (e.g., $\leq 35\%$, 30%, 25%, 20%, 15%, 10%, or 5%; e.g., 0-40%, 0-35%, 0-25%, 0-15%, 0-10%, 0-5%, 5-15%, 15-30%, 30-40%, 10-30%, 20-40%, 30-40%, 20-30%, or 10-20%; e.g., about 0%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40%). In some examples, the rate of serious adverse events related to mosunetuzumab in the population of subjects is $\leq 30\%$. In some examples, the rate of serious adverse events related to mosunetuzumab in the population of subjects is $\leq 35\%$.

20 In some examples, the rate of cytokine release syndrome having a grade of 3 or higher (as defined by the American Society for Transplantation and Cellular Therapy, 2018; ASTCT) in the population of subjects is $\leq 5\%$ (e.g., $\leq 4\%$, 3%, 2%, or 1%; e.g., 0-5%, 1-5%, 2-5%, 3-5%, 4-5%, 1-3%, 2-4%, or 0-3%; e.g., about 0%, about 1%, about 2%, about 3%, about 4%, or about 5%). In some examples, the rate of cytokine release syndrome having a grade of 3 or higher (as defined by the ASTCT) in the population of subjects is $\leq 3\%$.

25 In some examples, the rate of cytokine release syndrome of any grade (as defined by the ASTCT) in the population of subjects is $\leq 40\%$ (e.g., $\leq 35\%$, 30%, 25%, 20%, 15%, 10%, or 5%; e.g., 0-40%, 0-35%, 0-25%, 0-15%, 0-10%, 0-5%, 5-15%, 15-30%, 25-40%, 10-30%, 20-40%, 25-35%, 35-40%, 30-40%, 20-30%, or 10-20%; e.g., about 0%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40%). In some examples, the rate of cytokine release syndrome of any grade (as defined by the ASTCT) in the population of subjects is $\leq 30\%$. In some examples, the rate of cytokine release syndrome of any grade (as defined by the ASTCT) in the population of subjects is $\leq 50\%$ (e.g., $\leq 45\%$; e.g., 40-50%, 30-50%, 20-50%, 10-50%, 0-50%, 40-45%, 30-35%, 20-45%, 10-45%, 0-45%; e.g., about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50%).

30 In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for achieving an objective response, a complete response, or progression-free survival in a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle, a second 21-day dosing cycle, and a third 21-day dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab to be administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg. In one example, the disclosure provides a method of achieving an objective response, a complete response, or progression-free survival in a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL), wherein the method comprises intravenously administering to the subject mosunetuzumab in a

dosing regimen comprising at least a first 21-day (± 1 day) dosing cycle, a second 21-day (± 1 day) dosing cycle, and a third 21-day (± 1 day) dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, or $\pm$ 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, or $\pm$ 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg (e.g., 30 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, or $\pm$ 3 mg; e.g., 30 mg). In some examples, the C1D1 is 1 $\pm$ 0.2 mg, the C1D2 is 2 $\pm$ 0.4 mg, the C1D3 is 60 $\pm$ 12 mg, the C2D1 is 60 $\pm$ 12 mg, and the C3D1 is 30 $\pm$ 6 mg.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for achieving an objective response, a complete response, or progression-free survival in a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising eight 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg. In one example, the disclosure provides a method of achieving an objective response, a complete response, or progression-free survival in a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL), wherein the method comprises intravenously administering to the subject mosunetuzumab in a dosing regimen comprising eight 21-day (± 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, or $\pm$ 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, or $\pm$ 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg (e.g., 30 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, or $\pm$ 3 mg; e.g., 30 mg). In some examples, the C1D1 is 1 $\pm$ 0.2 mg, the C1D2 is 2 $\pm$ 0.4 mg, the C1D3 is 60 $\pm$ 12 mg, the C2D1 is 60 $\pm$ 12 mg, and each of the C3D1-C8D1 is 30 $\pm$ 6 mg.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for achieving an objective response, a complete response, or progression-free survival in a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising 17 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg. In one example, the disclosure provides a method of achieving an objective response, a complete response, or progression-free survival in a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL), wherein the method comprises intravenously administering to the subject mosunetuzumab in a dosing regimen comprising 17 21-day (± 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, or ± 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, or ± 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg (e.g., 30 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, or ± 3 mg; e.g., 30 mg). In some examples, the C1D1 is 1 ± 0.2 mg, the C1D2 is 2 ± 0.4 mg, the C1D3 is 60 ± 12 mg, the C2D1 is 60 ± 12 mg, and each of the C3D1-C17D1 is 30 ± 6 mg.

In some examples, the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy. In some examples, the two or more prior lines of therapy comprise an anti-CD20 monoclonal antibody (e.g., rituximab), an alkylating agent (e.g., bendamustine, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, carmustine, lomustine, streptozocin, busulfan, dacarbazine, temozolomide, altretamine, or thiotepa), or both an anti-CD20 monoclonal antibody and an alkylating agent.

In some examples, the R/R NHL is R/R follicular lymphoma (FL), R/R transformed FL (trFL), or R/R diffuse large B cell lymphoma (DLBCL). In some examples, the R/R NHL is R/R FL. In some examples, the R/R FL is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. *Blood* 2016; 127:2375-90).

In some examples, mosunetuzumab is administered by intravenous infusion.

In some examples, the subject achieves an objective response. In some examples, the subject achieves a complete response. In some examples, the progression-free survival is maintained for ≥ 12 months (e.g., ≥ 12 , 13, 14, 15, 18, 21, 24, 27, 30, 33, 36 months, or more; e.g., 12-15 months, 12-18 months, 12-21 months, 12-24 months, 12-30 months, 12-36 months, 15-18 months, 15-24 months, 18-24 months, 24-36 months, 18-36 months, or more; e.g., 12, 13, 14, 15, 16,

17, 18, 19, 20, 21, 24, 27, 30, 33, 36 months, or more). In some examples, the progression-free survival is maintained for ≥ 18 months.

In some examples, the method further comprises administering to the subject or to each subject in the population of subjects one or more (e.g., one, two, three, four, five, six, or more)

5 additional therapeutic agents.

In some examples, the one or more (e.g., one, two, three, four, five, six, or more) additional therapeutic agents comprises tocilizumab.

In some examples, the one or more (e.g., one, two, three, four, five, six, or more) additional therapeutic agents comprises a corticosteroid. In some examples, the corticosteroid comprises
10 dexamethasone or methylprednisolone. In some examples, the corticosteroid is administered to the subject or to each subject in the population of subjects at least one hour (e.g., 60, 70, 80, 90, 120, 150, 180, 210, 240, 300 minutes, or more) prior to the administration of any dose of mosunetuzumab. In some examples, the corticosteroid is only administered during dosing cycle 1 or dosing cycle 2. In some examples, the corticosteroid is additionally administered during one or more dosing cycles after
15 dosing cycle 2 (e.g., in dosing cycle 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and/or 17). In some examples, the corticosteroid is administered intravenously. In some examples, the corticosteroid comprises dexamethasone and is administered at a dose of about 20 mg (e.g., 20 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, or $\pm$ 2 mg; e.g., 20 mg). In some examples, the corticosteroid comprises
20 methylprednisolone and is administered at a dose of about 80 mg (e.g., 80 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 8 mg, $\pm$ 7 mg, or $\pm$ 8 mg; e.g., 80 mg).

In some examples, the one or more (e.g., one, two, three, four, five, six, or more) additional therapeutic agents comprises an anti-histamine. In some examples, the anti-histamine is
25 administered to the subject or to each subject in the population of subjects at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of any dose of mosunetuzumab. In some examples, the anti-histamine is only administered during dosing cycle 1 or dosing cycle 2. In some examples, the anti-histamine is additionally administered during one or more dosing cycles after dosing cycle 2 (e.g., in dosing cycle 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
30 14, 15, 16, and/or 17). In some examples, the anti-histamine is administered orally or intravenously. In some examples, the anti-histamine comprises diphenhydramine hydrochloride and is administered at a dose of about 50-100 mg (e.g., 50-90 mg, 50-80 mg, 50-70 mg, 50-60 mg, 60-100 mg, 70-100 mg, 80-100 mg, 90-100 mg, 70-80 mg, 60-90 mg, 60-80 mg, 70-90 mg, or 65-85 mg; e.g., about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg,
35 about 90 mg, about 95 mg, or about 100 mg).

In some examples, the one or more (e.g., one, two, three, four, five, six, or more) additional therapeutic agents comprises an anti-pyretic. In some examples, the anti-pyretic is administered to the subject or to each subject in the population of subjects at least 30 minutes (e.g., 30, 35, 40, 45,
40 50, 60, 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of any dose of mosunetuzumab. In some examples, the anti-pyretic is only administered during dosing

cycle 1 or dosing cycle 2. In some examples, the anti-pyretic is additionally administered during one or more dosing cycles after dosing cycle 2 (e.g., in dosing cycle 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and/or 17). In some examples, the anti-pyretic is administered orally. In some examples, the anti-pyretic comprises acetaminophen and is administered at a dose of about 500-1000 mg (e.g., 500-900 mg, 500-800 mg, 500-700 mg, 500-600 mg, 600-1000 mg, 700-1000 mg, 800-1000 mg, 900-1000 mg, 700-800 mg, 600-900 mg, 600-800 mg, 700-900 mg, or 650-850 mg; e.g., about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg).

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle, a second 21-day dosing cycle, and a third 21-day dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab to be administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg, wherein the subject has relapsed after, or is refractory to, two or more prior lines of therapy. In one example, the disclosure provides a method of treating a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to the subject mosunetuzumab in a dosing regimen comprising at least a first 21-day (± 1 day) dosing cycle, a second 21-day (± 1 day) dosing cycle, and a third 21-day (± 1 day) dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, or ± 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, or ± 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg (e.g., 30 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, or ± 3 mg; e.g., 30 mg), wherein the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy. In some examples, the C1D1 is 1 ± 0.2 mg, the C1D2 is 2 ± 0.4 mg, the C1D3 is 60 ± 12 mg, the C2D1 is 60 ± 12 mg, and the C3D1 is 30 ± 6 mg.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising eight 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg, wherein the subject has relapsed after, or is refractory to, two or more prior lines of therapy. In one example, the disclosure provides a method of treating a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to the subject mosunetuzumab in a dosing regimen comprising eight 21-day (± 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, or ± 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, or ± 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg (e.g., 30 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, or ± 3 mg; e.g., 30 mg), wherein the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy. In some examples, the C1D1 is 1 ± 0.2 mg, the C1D2 is 2 ± 0.4 mg, the C1D3 is 60 ± 12 mg, the C2D1 is 60 ± 12 mg, and the C3D1-C8D1 is 30 ± 6 mg.

0.075 mg, $\pm$ 0.1 mg, or $\pm$ 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg (e.g., 30 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, or $\pm$ 3 mg; e.g., 30 mg), wherein the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy. In some examples, the C1D1 is 1 $\pm$ 0.2 mg, the C1D2 is 2 $\pm$ 0.4 mg, the C1D3 is 60 $\pm$ 12 mg, the C2D1 is 60 $\pm$ 12 mg, and each of the C3D1-C8D1 is 30 $\pm$ 6 mg.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising 17 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg, wherein the subject has relapsed after, or is refractory to, two or more prior lines of therapy. In one example, the disclosure provides a method of treating a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to the subject mosunetuzumab in a dosing regimen comprising 17 21-day ($\pm$ 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 ($\pm$ 1 day), and 15 ($\pm$ 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, or $\pm$ 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, or $\pm$ 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg (e.g., 30 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, or $\pm$ 3 mg; e.g., 30 mg), wherein the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy. In some examples, the C1D1 is 1 $\pm$ 0.2 mg, the C1D2 is 2 $\pm$ 0.4 mg, the C1D3 is 60 $\pm$ 12 mg, the C2D1 is 60 $\pm$ 12 mg, and each of the C3D1-C17D1 is 30 $\pm$ 6 mg.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle, a second 21-day dosing cycle, and a third 21-day dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab to be administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg, wherein the subject has relapsed after, or is refractory to, two or more prior lines of therapy, and wherein the dosing regimen further comprises: (i) a corticosteroid for administration to the subject, wherein a single dose of the corticosteroid is to be administered to the subject at least one hour prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; (ii) an anti-histamine for administration to the subject, wherein a single dose of the anti-histamine is to be administered to the subject at least 30 minutes prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; and/or (iii) an anti-pyretic for administration to the subject, wherein a single dose of the anti-pyretic is to be administered to the subject at least 30 minutes prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab. In one example, the disclosure provides a method of treating a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R

DLBCL, or R/R trFL) comprising intravenously administering to the subject mosunetuzumab in a dosing regimen comprising at least a first 21-day (± 1 day) dosing cycle, a second 21-day (± 1 day) dosing cycle, and a third 21-day (± 1 day) dosing cycle, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, or $\pm$ 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, or $\pm$ 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, $\pm$ 3 mg, $\pm$ 4 mg, $\pm$ 5 mg, $\pm$ 6 mg; e.g., 60 mg); and (c) the third dosing cycle comprises a single dose (C3D1) of mosunetuzumab administered on Day 1 of the third dosing cycle, wherein the C3D1 is about 30 mg (e.g., 30 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1 mg, $\pm$ 1.5 mg, $\pm$ 2 mg, or $\pm$ 3 mg; e.g., 30 mg), wherein the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy, and wherein the dosing regimen further comprises: (i) administering a corticosteroid, wherein a single dose of the corticosteroid is administered to the subject at least one hour (e.g., 60, 70, 80, 90, 120, 150, 180, 210, 240, 300 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; (ii) administering an anti-histamine, wherein a single dose of the anti-histamine is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; and/or (iii) administering an anti-pyretic, wherein a single dose of the anti-pyretic is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab. In some examples, the C1D1 is 1 $\pm$ 0.2 mg, the C1D2 is 2 $\pm$ 0.4 mg, the C1D3 is 60 $\pm$ 12 mg, the C2D1 is 60 $\pm$ 12 mg, and the C3D1 is 30 $\pm$ 6 mg.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising eight 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg, wherein the subject has relapsed after, or is refractory to, two or more prior lines of therapy, and wherein the dosing regimen further comprises: (i) a corticosteroid for administration to the subject, wherein a single dose of the corticosteroid is to be administered to the subject at least one hour prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; (ii) an anti-histamine for administration to the subject, wherein a single dose of the anti-histamine is to be administered to the subject at least 30 minutes prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; and/or (iii) an anti-pyretic for administration to the subject, wherein a single dose of the anti-pyretic is to be administered to the subject at least 30 minutes prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab. In one example, the disclosure provides a method of treating a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to the subject mosunetuzumab in a dosing regimen comprising eight 21-day (± 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, or $\pm$ 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, or $\pm$ 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg $\pm$ 0.01 mg, $\pm$ 0.025 mg, $\pm$ 0.05 mg, $\pm$ 0.075 mg, $\pm$ 0.1 mg, $\pm$ 0.2 mg, $\pm$ 0.3 mg, $\pm$ 0.4 mg, $\pm$ 0.5 mg, $\pm$ 0.75 mg, $\pm$ 1

mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); and (c) the third to eighth dosing cycles each comprises a single dose (C3D1-C8D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C8D1 is about 30 mg (e.g., 30 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, or ± 3 mg; e.g., 30 mg), wherein the subject has relapsed after, or is refractory to, two or more prior (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) lines of therapy, and wherein the dosing regimen further comprises: (i) administering a corticosteroid, wherein a single dose of the corticosteroid is administered to the subject at least one hour (e.g., 60, 70, 80, 90, 120, 150, 180, 210, 240, 300 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; (ii) administering an anti-histamine, wherein a single dose of the anti-histamine is administered to the subject at least 30 (e.g., 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 150, 180 minutes, or more) minutes prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; and/or (iii) administering an anti-pyretic, wherein a single dose of the anti-pyretic is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab. In some examples, the C1D1 is 1 ± 0.2 mg, the C1D2 is 2 ± 0.4 mg, the C1D3 is 60 ± 12 mg, the C2D1 is 60 ± 12 mg, and each of the C3D1-C8D1 is 30 ± 6 mg.

In one aspect, the disclosure provides use of mosunetuzumab in the manufacture of a medicament for treating a subject aged about 65 years or older having an R/R NHL, wherein mosunetuzumab is formulated for intravenous administration to the subject according to a dosing regimen comprising 17 21-day dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab to be administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg; (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg; and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab to be administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg, wherein the subject has relapsed after, or is refractory to, two or more prior lines of therapy, and wherein the dosing regimen further comprises: (i) a corticosteroid for administration to the subject, wherein a single dose of the corticosteroid is to be administered to the subject at least one hour prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; (ii) an anti-histamine for administration to the subject, wherein a single dose of the anti-histamine is to be administered to the subject at least 30 minutes prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; and/or (iii) an anti-pyretic for administration to the subject, wherein a single dose of the anti-pyretic is to be administered to the subject at least 30 minutes prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab. In one example, the disclosure provides a method of treating a subject aged about 65 years or older (e.g., 65 years or older, 70 years or older, 75 years or older, 80 years or older, 85 years or older, 90 years or older, 95 years or older, or 100 years or older) having an R/R NHL (e.g., R/R FL, R/R DLBCL, or R/R trFL) comprising intravenously administering to the subject mosunetuzumab in a dosing regimen comprising 17 21-day (± 1 day) dosing cycles, wherein: (a) the first three-dose dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab administered on Days 1, 8 (± 1 day), and 15 (± 1 day), respectively, of the first dosing cycle, wherein the C1D1 is about 1 mg (e.g., 1 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, or ± 0.1 mg; e.g., 1 mg), the C1D2 about 2 mg (e.g., 2 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, or ± 0.2 mg; e.g., 2 mg), and the C1D3 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 60 mg (e.g., 60 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, ± 3 mg, ± 4 mg, ± 5 mg, ± 6 mg; e.g., 60 mg); and (c) the third to 17th dosing cycles each comprises a single dose (C3D1-C17D1) of mosunetuzumab administered on Day 1 of each respective dosing cycle, wherein each of the C3D1-C17D1 is about 30 mg (e.g., 30 mg ± 0.01 mg, ± 0.025 mg, ± 0.05 mg, ± 0.075 mg, ± 0.1 mg, ± 0.2 mg, ± 0.3 mg, ± 0.4 mg, ± 0.5 mg, ± 0.75 mg, ± 1 mg, ± 1.5 mg, ± 2 mg, or ± 3 mg;

e.g., 30 mg), wherein the subject has relapsed after, or is refractory to, two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, 11, 12, or more) prior lines of therapy, and wherein the dosing regimen further comprises: (i) administering a corticosteroid, wherein a single dose of the corticosteroid is administered to the subject at least one hour (e.g., 60 70, 80, 90, 120, 150, 180, 210, 240, 300 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; (ii) administering an anti-histamine, wherein a single dose of the anti-histamine is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab; and/or (iii) administering an anti-pyretic, wherein a single dose of the anti-pyretic is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of each of the C1D1, C1D2, C1D3, and C2D1 of mosunetuzumab. In some examples, the C1D1 is 1 ± 0.2 mg, the C1D2 is 2 ± 0.4 mg, the C1D3 is 60 ± 12 mg, the C2D1 is 60 ± 12 mg, and each of the C3D1-C17D1 is 30 ± 6 mg.

In some examples, (i) a single dose of the corticosteroid is administered prior to the administration of any dose of mosunetuzumab in any of the one or more of any of the dosing cycles after the second dosing cycle (e.g., prior to administration of the C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, and/ or C14D1 of mosunetuzumab); (ii) a single dose of the anti-histamine is administered prior to the administration of any dose of mosunetuzumab in any of the one or more of any of the dosing cycles after the second dosing cycle (e.g., prior to administration of the C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, and/ or C14D1 of mosunetuzumab); and/or (iii) a single dose of the anti-pyretic is administered prior to the administration of any dose of mosunetuzumab in any of the one or more of any of the dosing cycles after the second dosing cycle (e.g., prior to administration of the C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, and/ or C14D1 of mosunetuzumab).

In some examples, (i) the corticosteroid is administered intravenously; (ii) the anti-histamine is administered orally or intravenously; and/or (iii) the anti-pyretic is administered orally.

In some examples, (i) the corticosteroid comprises dexamethasone and is administered at a dose of about 20 mg (e.g., $20 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, or $\pm 2 \text{ mg}$; e.g., 20 mg) or the corticosteroid comprises methylprednisolone and is administered at a dose of about 80 mg (e.g., $80 \text{ mg} \pm 0.01 \text{ mg}$, $\pm 0.025 \text{ mg}$, $\pm 0.05 \text{ mg}$, $\pm 0.075 \text{ mg}$, $\pm 0.1 \text{ mg}$, $\pm 0.2 \text{ mg}$, $\pm 0.3 \text{ mg}$, $\pm 0.4 \text{ mg}$, $\pm 0.5 \text{ mg}$, $\pm 0.75 \text{ mg}$, $\pm 1 \text{ mg}$, $\pm 1.5 \text{ mg}$, $\pm 2 \text{ mg}$, $\pm 3 \text{ mg}$, $\pm 4 \text{ mg}$, $\pm 5 \text{ mg}$, $\pm 8 \text{ mg}$, $\pm 7 \text{ mg}$, or $\pm 8 \text{ mg}$; e.g., 80 mg); (ii) the anti-histamine comprises diphenhydramine hydrochloride and is administered at a dose of about 50-100 mg (e.g., 50-90 mg, 50-80 mg, 50-70 mg, 50-60 mg, 60-100 mg, 70-100 mg, 80-100 mg, 90-100 mg, 70-80 mg, 60-90 mg, 60-80 mg, 70-90 mg, or 65-85 mg; e.g., about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg); and/or (iii) the anti-pyretic comprises acetaminophen and is administered at a dose of about 500-1000 mg (e.g., 500-900 mg, 500-800 mg, 500-700 mg, 500-600 mg, 600-1000 mg, 700-1000 mg, 800-1000 mg, 900-1000 mg, 700-800 mg, 600-900 mg, 600-800

mg, 700-900 mg, or 650-850 mg; e.g., about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg).

In some examples, the subject described herein is a human subject.

5

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 is a schematic diagram showing the overview of a step-load-base dosing of mosunetuzumab. The vertical bars indicate the relative amount of administered mosunetuzumab. Described is a step load-base dosing of 1/2/60/60/30 mg. Patients are administered a first dose (C1D1 dose; i.e., a first step dose) of about 1 mg mosunetuzumab on Day 1 of dosing cycle (Cycle) 1, followed by a second dose (C1D2 dose; i.e., a second step dose) of about 2 mg mosunetuzumab on Day 8 of Cycle 1. The patients are then administered a third dose (C1D3 dose; i.e., a first loading dose) of about 60 mg mosunetuzumab on Day 15 of Cycle 1, followed by first dose (C2D1 dose; i.e., a second loading dose) of about 60 mg mosunetuzumab on Day 1 of Cycle 2. Thereafter, the patient is administered base doses of about 30 mg mosunetuzumab on Day 1 of each subsequent dosing cycle (e.g., C3D1 dose, C4D1 dose, etc.). The patients are initially administered 6 doses (i.e., base doses) on Day 1 of Cycle 3 (C3D1) to Day 1 of Cycle 8 (C8D1). Patients who do not achieve CR following 8 dosing cycles of treatment continue to receive base doses of about 30 mg mosunetuzumab for 8 or 17 additional cycles of treatment. ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; R/R, relapsed/refractory.

DETAILED DESCRIPTION

The present invention involves methods of treating an elderly subject (i.e., aged about 65 years or older) or a population of elderly subjects (i.e., each aged about 65 years or older) having a relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL; e.g., a diffuse large B cell lymphoma (DLBCL; e.g., a Richter's Transformation), a follicular lymphoma (FL; e.g., a Grade 1 FL, a Grade 2 FL, a Grade 3 FL (e.g., a Grade 3a FL, or a Grade 3b FL), or a transformed FL (trFL); e.g., an R/R NHL, R/R DLBCL, R/R FL, or R/R trFL) by intravenously administering (e.g., via intravenous infusion) to the subject an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab) in a dosing regimen comprising at least a first dosing cycle, a second dosing cycle, and a third dosing cycle. In some instances, the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab, wherein the C1D1 is from about 1 mg, the C1D2 is about 2 mg, and the C1D3 is about 60 mg. In some instances, the second dosing cycle includes a single dose (C2D1) of mosunetuzumab of about 60 mg. In some instances, the third dosing cycle includes a single dose (C3D1) of mosunetuzumab of about 30 mg.

As previously noted, the invention is based, in part, on the discovery that dosing regimens involving administration of mosunetuzumab over multiple dosing cycles (e.g., wherein the first dosing cycle is a step-up, fractionated dosing cycle) including a relatively high third dose (C1D3) and/or a dose of a second dosing cycle (C2D1) that is greater in amount than a dose of the third dosing cycle (C3D1) and/or additional dosing cycles can effectively treat subjects having an R/R NHL (e.g., R/R